{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T21:03:30Z","timestamp":1761253410525,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.thromres.2019.09.033","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T12:27:11Z","timestamp":1571833631000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-1333","authenticated-orcid":false,"given":"Eduardo","family":"Ramacciotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.thromres.2019.09.033_bb0005","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.thromres.2019.09.033_bb0010","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"38","key":"10.1016\/j.thromres.2019.09.033_bb0015","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology","volume":"34","author":"Task Force M","year":"2013","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.thromres.2019.09.033_bb0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.thromres.2019.09.033_bb0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Warfarin Antiplatelet Vascular Evaluation Trial I","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.thromres.2019.09.033_bb0030","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators E","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.thromres.2019.09.033_bb0035","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Investigators E-P","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2019.09.033_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2019.09.033_bb0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.thromres.2019.09.033_bb0050","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.09.033_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.011","article-title":"Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)","volume":"199","author":"Capell","year":"2018","journal-title":"Am. Heart J."},{"issue":"14","key":"10.1016\/j.thromres.2019.09.033_bb0060","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9683","key":"10.1016\/j.thromres.2019.09.033_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet."},{"issue":"14","key":"10.1016\/j.thromres.2019.09.033_bb0070","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2019.09.033_bb0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/ATVBAHA.118.310960","article-title":"Advances in antithrombotic therapy","volume":"39","author":"Weitz","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.thromres.2019.09.033_bb0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2019.09.033_bb0085","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2007.11.057","article-title":"Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events","volume":"101","author":"Bowry","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"19","key":"10.1016\/j.thromres.2019.09.033_bb0090","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9038","key":"10.1016\/j.thromres.2019.09.033_bb0095","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet."},{"issue":"16","key":"10.1016\/j.thromres.2019.09.033_bb0100","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.thromres.2019.09.033_bb0105","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s40265-017-0806-1","article-title":"Dual antiplatelet therapy duration: reconciling the inconsistencies","volume":"77","author":"Costa","year":"2017","journal-title":"Drugs."},{"issue":"5","key":"10.1016\/j.thromres.2019.09.033_bb0110","doi-asserted-by":"crossref","first-page":"630","DOI":"10.21037\/cdt.2018.10.01","article-title":"The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short","volume":"8","author":"Costa","year":"2018","journal-title":"Cardiovasc. Diagn. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2019.09.033_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1074248417708617","article-title":"Role for thrombin receptor antagonism with vorapaxar in secondary prevention of atherothrombotic events: from bench to bedside","volume":"23","author":"Moon","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2019.09.033_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","article-title":"Platelet thrombin receptor antagonism and atherothrombosis","volume":"31","author":"Angiolillo","year":"2010","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.thromres.2019.09.033_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.thromres.2019.09.033_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2019.09.033_bb0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10117","key":"10.1016\/j.thromres.2019.09.033_bb0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.thromres.2019.09.033_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.23736\/S0392-9590.18.03998-6","article-title":"Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint","volume":"37","author":"Ramacciotti","year":"2018","journal-title":"Int. Angiol."},{"issue":"10117","key":"10.1016\/j.thromres.2019.09.033_bb0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet."},{"issue":"25","key":"10.1016\/j.thromres.2019.09.033_bb0155","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2019.09.033_bb0160","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCRESAHA.118.313141","article-title":"Synergy of dual pathway inhibition in chronic cardiovascular disease","volume":"124","author":"Coppens","year":"2019","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.thromres.2019.09.033_bb0165","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS trial","volume":"139","author":"Sharma","year":"2019","journal-title":"Circulation."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819304426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819304426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:39:29Z","timestamp":1758735569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384819304426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":33,"alternative-id":["S0049384819304426"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2019.09.033","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2019.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}